17 Aug Tecentriq® (atezolizumab): Risk of Severe Cutaneous Adverse Reactions (SCARs) and Immune-related myositis
Posted at 12:36h
in
In collaboration with the South African Health Products Regulatory Authority (SAHPRA), Roche Products (Pty) Ltd would like to inform you of the risk of Severe Cutaneous Adverse Reactions (SCARs) and immune-related myositis associated with the use of Tecentriq® (azeolizumab).
2020 Nov
Download latest version
Document Number:
DHCPL
Version:
1
Date Updated:
19/11/2020
File Type:
pdf
Category:
Communication To Health Care Professionals